ClinicalTrials.gg
RecruitingNCT06340646Updated Jul 14, 2026

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)

An interventional study of Return of Genetic Results: Biomarker information from cancer cells and Return of Genetic Results: Inherited mutations related to cancer in Cholangiocarcinoma, Multiple Myeloma and Colon Cancer, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Oct 2022, registered Mar 2024).
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
990
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 109 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Planned enrollment
2nd of 279
990 · median 44
Started
2022
with 23 others
No phase
34 of 328
10 open now
Primary completion
2027-01
later than 30 of 108 live
Registered
274th of 328
by date
Lead sponsor
8 of 328
Washington University School of Medicine

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 2nd largest by planned enrollment of the 279 interventional ones that give a count, is one of 24 that started in 2022, is one of 34 with no phase, reaches primary completion later than 30 of the 108 other live ones, and was the 274th registered.

Cholangiocarcinoma

826 studies on the registry are indexed under Cholangiocarcinoma; 289 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

The overall goal of the WU-PE-CGS is to build a rigorous, scientific evidence base for approaches that direct engagement of cancer patients and post-treatment cancer survivors as participants in cancer research, and to investigate the impact of directly engaging participants in decisions regarding returning of genomic results on participants' health and satisfaction. Participants in this study will be presented with the choice of types of genomic results to receive, and the Engagement Optimization Unit (EOU) will investigate the impact of this intervention on participant knowledge, expectations of benefit, personal utility, and decisional conflict.

03

Conditions studied

  • Cholangiocarcinoma
  • Multiple Myeloma
  • Colon Cancer
  • Rectal Cancer

Keywords

  • Participant engagement
  • Genetic testing
  • Cholangiocarcinoma
  • Multiple Myeloma
  • Colorectal cancer
  • Underrepresented populations
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility Criteria:

  • Patients with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer.

    • If diagnosed with multiple myeloma, must be African-American.
    • If diagnosed with colon or rectal cancer, must be African-American AND must be no older than 65 years old at the time of diagnosis.
    • At least 18 years old
    • Able to understand and willing to sign an IRB-approved written document
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
990 participants (estimated)

Study arms

  • No intervention
    No Return of Genetic Results

    Participants will undergo germline genomic sequencing as part of consenting to the WU-PE-CGS program. Participants will be given the option to receive the results from the genomic sequencing. After they consent to the study, the types of results available to them will be explained by research staff. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information

  • Experimental
    Return of Genetic Results

    Participants will undergo germline genomic sequencing as part of consenting to the WU-PE-CGS program. Participants will be given the option to receive the results from the genomic sequencing. After they consent to the study, the types of results available to them will be explained by research staff. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues. These choices will be presented to them via a discussion with study staff with accompanying paper information

    Other: Return of Genetic Results: Biomarker information from cancer cells · Other: Return of Genetic Results: Inherited mutations related to cancer · Other: Return of Genetic Results: Inherited mutations related to other medical issues

Interventions

  • OtherReturn of Genetic Results: Biomarker information from cancer cells

    Participants will receive a novel return of results report that is tailored to their choices.

  • OtherReturn of Genetic Results: Inherited mutations related to cancer

    Participants will receive a novel return of results report that is tailored to their choices.

  • OtherReturn of Genetic Results: Inherited mutations related to other medical issues

    Participants will receive a novel return of results report that is tailored to their choices.

06

What researchers measure

Primary outcomes

  1. Participant knowledge of clinical genetic testing

    11-item, Likert scale. This scale has 5 points ranging from strongly agree to strongly disagree. 1=Strongly Agree, 2=Agree, 3=Neither Agree nor Disagree, 4=Disagree, 5=Strongly Disagree for items (4, 6-11) are scored such that 'strong disagree' reflects a correct response and 'somewhat disagree' reflects a less confident correct response in the correct direction. Negatively worded items (items 1, 2, 3, and 5) are reverse scored so that 'strongly agree' reflects a correct response and 'somewhat agree' reflect a less confident response in the correct direction. This will be scored by adding up the numbers for each of the 11 items regarding participant knowledge of clinical genetic testing. The total score ranges from 5 to 55. A higher score for the participant represents higher participant knowledge.

    Time frame: Through completion of follow-up (estimated to be 5 years)

  2. Participant expectations of benefit

    Participants will rate their expectation for 6 potential benefits of cancer genomic sequencing on a 4-point scale ranging from extremely unlikely to extremely likely. . 1=Strongly Agree, 2=Agree, 3=Disagree, 4=Strongly Disagree. This will be scored by adding up the numbers for each of the 8 items regarding participant expectations of benefit. The total score ranges from 6 to 24. A higher score for the participant represents higher levels of expectations.

    Time frame: Through completion of follow-up (estimated to be 5 years)

  3. Participant personal utility

    Participant personal utility will be measured on a 7-point scale ranging from not at all useful to extremely useful. 1=Not at all useful, 2=A little useful, 3=Somewhat useful, 4=Neutral, 5=Useful, 6=Very useful, 7=Extremely useful. This will be scored by adding up the numbers for each of the 14 items regarding participant personal utility. The total score ranges from 14 to 98. A higher score for the participant represents higher personal utility.

    Time frame: Through completion of follow-up (estimated to be 5 years)

Secondary outcomes

  1. Participant anxiety

    Participant anxiety will be measured using a 5-point Likert scale ranging from not at all to very much. 0=Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit, 4=Very much. This will be scored by adding up the numbers for each of the 6 items regarding participant cancer worry. The total score ranges from 0 to 24. A higher score for the participant represents higher participant cancer worry.

    Time frame: Through completion of follow-up (estimated to be 5 years)

  2. Participant satisfaction

    Satisfaction will be measured using a 5-point Likert scale ranging from extremely satisfied to not at all. 1=Not at all satisfied, 2=A little bit, 3=Somewhat, 4=Quite a bit, 5=Extremely satisfied. The total score ranges from 1 to 5. A higher score for the participant represents higher participant satisfaction.

    Time frame: Through completion of follow-up (estimated to be 5 years)

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Graham Colditz, M.D., DrPH, MPH · Contactcolditzg@wustl.edu · 314-454-7939
    • Bettina Drake, Ph.D., MPH · Contactdrakeb@wustl.edu · 314-747-4534
    • Graham Colditz, M.D., DrPH, MPH · Principal investigator
    • Li Ding, Ph.D. · Sub investigator
    • Bettina Drake, Ph.D. · Sub investigator
    • Ryan Fields, M.D. · Sub investigator
    • Yin Cao, ScD, MPH · Sub investigator
    • Feng Chen, Ph.D. · Sub investigator
    • Patricia Dickson, M.D. · Sub investigator
    • Eric Duncavage, M.D. · Sub investigator
    • Mark Fiala, MSW · Sub investigator
    • Aimee James, Ph.D., MPH · Sub investigator
    • Reyka Jayasinge, Ph.D. · Sub investigator
    • Kian-Huat Lim, M.D., Ph.D. · Sub investigator
    • Erin Linnenbringer, Ph.D., MS · Sub investigator
    • Jessica Mozersky, Ph.D. · Sub investigator
    • Mary Politi, Ph.D. · Sub investigator
    • David Spencer, M.D., Ph.D. · Sub investigator
    • Tunji Toriola, M.D., Ph.D., MPH · Sub investigator
    • Ravi Vij, M.D., MBA · Sub investigator
    • Mark Watson, M.D., Ph.D. · Sub investigator
    • Fei Wan, Ph.D. · Sub investigator
    • Mike Wendl, DSC, MS, PHS · Sub investigator
    • Matthew Wyczalkowski, Ph.D. · Sub investigator
    • Stephanie Solomon Cargill, Ph.D., MSPH · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Will share all data, software and know-how generated during the course of this work, without limitations except as prevented by prior agreement. This will include both the final datasets, as well as the data necessary to complete the aims. Will disseminate results from this research through presentations at public lectures, scientific institutions and meetings, and/or publication in major journals. All final peer-reviewed manuscripts that arise from this proposal will be submitted to the digital archive PubMed Central. Wherever applicable, data will be deposited to appropriate public repositories. All participants whose genomic data are collected will be consented for broad data sharing, and their genomic data will be included in the study deposits. Data documentation and de-identified data will be deposited for sharing along with phenotypic data, which includes demographics and diagnosis, consistent with applicable laws and regulations.

Supporting information: Study protocol, Statistical analysis plan

Time frame: The investigators agree to deposit data into database of Genotypes and Phenotypes (dbGaP) repository after data cleaning and quality control as soon as possible but no later than within three months, or upon acceptance of the data for publication, or public disclosure of a submitted patent application, whichever is earlier. When data are released from dbGaP, the data will be made available to the Genomic Data Commons (GDC).

Access criteria: The investigators agree that they will identify where the data will be available (dbGaP and GDC) and how to access the data in any publications and presentations that they author or co-author about these data, as well as acknowledge the repository and funding source in any publications and presentations. As they will be using the database of Genotypes and Phenotypes (dbGaP), which is an NIH-funded repository, this repository has policies and procedures in place that will provide data access to qualified researchers, fully consistent with NIH data sharing policies and applicable laws and regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Jan 2027, 51 months after the start.

Of 66 non-industry interventional studies with no phase under Cholangiocarcinoma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 28. This study's planned 51 months is above that.

Counting every sponsor, half of 67 studies reached it within 43 months; a quarter within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2024
First posted
Apr 1, 2024
StartActual
Oct 18, 2022
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06340646
Collaborators
National Cancer Institute (NCI), The Foundation for Barnes-Jewish Hospital
Responsible party
Sponsor
First posted
Apr 1, 2024
Start date
Oct 18, 2022
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Graham Colditz, M.D., DrPH, MPH
Contact
colditzg@wustl.edu
314-454-7939
Bettina Drake, Ph.D., MPH
Contact
drakeb@wustl.edu
314-747-4534
Graham Colditz, M.D., DrPH, MPH
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion